Mesenchymal stem cells and uses therefor

Patent metadata

Field	Value
Publication number	US-10716814-B2
Application number	US-201816206235-A
Country	US
Kind code	B2
Filing date	Nov 30, 2018
Priority date	Mar 22, 2004
Publication date	Jul 21, 2020
Grant date	Jul 21, 2020

Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

First claim

The invention claimed is:

1. A method of reducing inflammation in the gut, skin, or liver in a patient in need thereof comprising administering cultured mesenchymal stem cells to the patient in an amount effective to reduce the inflammation, wherein the mesenchymal stem cells are not genetically engineered with one or more polynucleotides encoding a therapeutic agent.

2. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic.

3. The method of claim 1 , wherein the mesenchymal stem cells are autologous.

4. The method of claim 1 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium for inj ecti on.

5. The method of claim 1 , wherein the mesenchymal stem cells are administered intravenously.

6. The method of claim 1 , wherein the mesenchymal stem cells are administered intraarterially.

7. The method of claim 1 , wherein the mesenchymal stem cells are administered in amount of about 1×10 5 cells/kg to about 5×10 7 cells per kg.

8. The method of claim 1 , wherein the mesenchymal stem cells are administered in amount of about 1×10 6 cells/kg to about 5×10 6 cells per kg.

9. The method of claim 1 , wherein the mesenchymal stem cells were isolated from marrow.

10. The method of claim 9 , wherein the marrow is iliac crest marrow.

11. The method of claim 1 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

12. The method of claim 2 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection.

13. The method of claim 2 , wherein the mesenchymal stem cells are administered intravenously.

14. The method of claim 2 , wherein the mesenchymal stem cells are administered intraarterially.

15. The method of claim 2 , wherein the mesenchymal stem cells are administered in amount of about 1×10 5 cells/kg to about 5×10 7 cells per kg.

16. The method of claim 2 , wherein the mesenchymal stem cells are administered in amount of about 1×10 6 cells/kg to about 5×10 6 cells per kg.

17. The method of claim 2 , wherein the mesenchymal stem cells were isolated from marrow.

18. The method of claim 17 , wherein the marrow is iliac crest marrow.

19. The method of claim 2 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

20. The method of claim 1 , wherein inflammation in the gut is reduced.

21. The method of claim 1 , wherein inflammation in the skin is reduced.

22. The method of claim 1 , wherein inflammation in the liver is reduced.

Assignees

• Mesoblast Int Sarl

Inventors

• Aggarwal Sudeepta
• Pittenger Mark F
• Varney Timothy

Classifications

• C12N5/0662 Primary

  Stem cells · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N5/0667

  Adipose-derived stem cells [ADSC]; Adipose stromal stem cells · CPC title